# Neurodevelopmental Effects of Antiseizure Medications (NEAM) - UG3 Phase

> **NCT05364853** · NA · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Epilepsy

## Interventions

- **BEHAVIORAL:** In-Person Testing
- **BEHAVIORAL:** Remote Testing

## Key facts

- **NCT ID:** NCT05364853
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study did not receive funding.
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364853, "Neurodevelopmental Effects of Antiseizure Medications (NEAM) - UG3 Phase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05364853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*